19.52 -0.47 (-2.35%) | 03-28 12:55 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 24.48 | 1-year : | 25.8 |
Resists | First : | 20.96 | Second : | 22.09 |
Pivot price | 20.05 | |||
Supports | First : | 19.14 | Second : | 15.93 |
MAs | MA(5) : | 19.9 | MA(20) : | 20.25 |
MA(100) : | 18.44 | MA(250) : | 16.51 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 30.3 | D(3) : | 32.4 |
RSI | RSI(14): 45 | |||
52-week | High : | 22.09 | Low : | 10.28 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KNSA ] has closed above bottom band by 20.4%. Bollinger Bands are 41.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 20.19 - 20.26 | 20.26 - 20.32 |
Low: | 19.67 - 19.77 | 19.77 - 19.84 |
Close: | 19.85 - 19.99 | 19.99 - 20.11 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Fri, 01 Mar 2024
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates - Simply Wall St
Fri, 01 Mar 2024
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect? - Yahoo Finance
Thu, 29 Feb 2024
Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice - Zacks Investment Research
Thu, 29 Feb 2024
Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) - Yahoo Finance
Thu, 29 Feb 2024
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript - Yahoo Finance
Wed, 28 Feb 2024
Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript - Seeking Alpha
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 40 (M) |
Shares Float | 32 (M) |
Held by Insiders | 3.9 (%) |
Held by Institutions | 89.8 (%) |
Shares Short | 2,780 (K) |
Shares Short P.Month | 2,760 (K) |
EPS | 0.2 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 6.23 |
Profit Margin | 5.2 % |
Operating Margin | 0.1 % |
Return on Assets (ttm) | -3.2 % |
Return on Equity (ttm) | 3.3 % |
Qtrly Rev. Growth | 34.7 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 6.75 |
EBITDA (p.s.) | -0.58 |
Qtrly Earnings Growth | 550 % |
Operating Cash Flow | 13 (M) |
Levered Free Cash Flow | 14 (M) |
PE Ratio | 98.25 |
PEG Ratio | 1.1 |
Price to Book value | 3.15 |
Price to Sales | 2.9 |
Price to Cash Flow | 59.06 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |